The FDA has approved Orserdu, a new oral medicine to treat metastatic, estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation.

FDA Approves Orserdu for Metastatic, ER+ Breast Cancer

Experimental Elacestrant Seems Effective for Breast Cancer Resistant to Other Types of Hormonal Therapy